Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human islets ...

Biomea Fusion, Inc. has presented promising clinical results for icovamenib, a novel therapy aimed at restoring beta-cell function in patients with type 2 diabetes, at the ATTD 2025 Conference.

Little is known about the impacts of therapy on adolescent patients with T2DM. In a recent study, adolescents with newly diagnosed T2DM had profound impairment of beta-cell function, but treatment ...

Type 2 diabetes (T2D) is a chronic and widely prevalent condition characterized by a progressive loss of glycemic control driven by both insulin resistance and β-cell dysfunction. The disease has long ...

A new study finds that short, functional-movement and resistance training workouts, called functional high-intensity training (F-HIT), may improve beta-cell function in adults with type 2 diabetes.

Researchers from the Icahn School of Medicine at Mount Sinai in New York have discovered a novel approach to protecting insulin-producing beta cells from the damaging effects of glucolipotoxicity—a ...

A researcher is planning on investigating potential treatments aimed at the root causes of type 1 diabetes. At the (MUSC), ...

Unlike our organs, cell organelles such as mitochondria are not fixed in place, but when, where, how, and why organelles move remain unclear. Research published in the Biophysical Journal shows that ...

The researchers investigated the impact of intermittent fasting on the beta cells. In the pancreas of mature mice, no negative effects on the beta cells were observed (here stained green). A recent ...